Euclises Pharmaceuticals is developing third-generation COX-2 inhibitors for use in the oncology setting, based on its proprietary Euclicoxib platform. Its lead candidate, ECP-1014, has been nominated and is the focus of ongoing IND-enabling preclinical work. The company has a development partnership with Guangzhou Institutes of Biomedicine and Health (GIBH), which is advancing a candidate in China and coordinating mutual development activities. Euclises completed a Series A that totals nearly $2 million to fund completion of preclinical studies and an IND filing for first human studies in cancer patients. The company is headquartered within the BioGenerator Accelerator Labs at CORTEX and is supported by investors including Cultivation Capital, BioGenerator, Missouri Technology Corporation, and the St. Louis Arch Angels. Management expects to raise additional funds by the end of the year to begin a first-in-human study in 2016. Euclises Pharmaceuticals is a drug discovery and development company focused on novel cyclooxygenase-2 (COX-2) inhibitors for use in the oncology setting. The company has developed a portfolio of Euclicoxib® COX-2 inhibitors optimized for cancer treatment and is in the process of selecting a lead clinical development candidate. Euclises was founded by John Talley, the inventor of celecoxib, and is headquartered in the BioGenerator Accelerator Labs at CORTEX in St. Louis. Management reports that its proprietary Euclicoxibs build on clinically validated anti-tumor activity seen with older COX-2 inhibitors while aiming to avoid the dose-limiting safety concerns of earlier generations. The company closed a $1.3 million Series A and will use proceeds to prepare its Euclicoxib product candidates for clinical trials and to advance a lead candidate toward the clinic. The leadership and board include CEO Rajesh Devraj, CSO John Talley, Cultivation Capital’s Rick Ryan, and investor representatives from BioGenerator and others.

Total raised

$3M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2015